INTS11

Across TCGA pan-cancer cohorts, INTS11 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated INTS11 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher INTS11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated INTS11 expression acts as an unfavorable survival marker.

BLCA, STAD, and SKCM are the cancer types where INTS11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.113	0.553	<.001	27	view →
STAD	OS	Median	III,IV	0.001	0.630	<.001	18	view →
SKCM	OS	Median	III,IV	0.371	0.711	.014	14	view →
CESC	DFS	Median	III,IV	0.215	0.634	.034	12	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

INTS11–BLCA (DFS)

Open the BLCA breakdown →